The University of Iowa College of Public Health
Iowa City, Iowa, 52246, United States
NCT Number: NCT02455310
This study will perform a retrospective analysis to evaluate the effectiveness of a multicomponent educational intervention to improve medication use and management of behavioral and psychological symptoms of dementia, relative to a statewide intervention that has been ongoing. Medication use and symptom severity outcomes will be compared among intervention counties and demographically similar non-intervention counties.
Looking for future studies?
Notify Me65 year and older
All sexes
Observational
Iowa City, Iowa, 52246, United States
This study will perform a retrospective analysis to evaluate the effectiveness of a multicomponent educational intervention to improve medication use and management of behavioral and psychological symptoms of dementia, relative to a statewide intervention that has been ongoing. Medication use and symptom severity outcomes will be compared among 29 intervention counties and 10 demographically similar non-intervention counties. The long-term effectiveness of the statewide intervention will also be evaluated. Medicare and Minimum Data set data from 2011 to 2014 will be used to evaluate prescribing and other outcomes in 1) outpatients with dementia, and 2) nursing home residents, based on exposure to interventions among healthcare and nursing home providers. Measurable goals included increasing the appropriateness of antipsychotic prescribing and reducing anticholinergic use. Effect modification will be evaluated by level of participation in the intervention and other prescriber and nursing home facility characteristics.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The multicomponent intervention included active dissemination of educational resources and optional participation in specialist consultation sessions for up to 6 months. The standard intervention included education through a website or conferences, including clinical tools to support implementation of best practices.
Time frame: Up to 4 years
Antipsychotic use
Time frame: Up to 4 years
Anticholinergic use
Time frame: Up to 4 years
Proportion of antipsychotic users with diabetes mellitus, hyperlipidemia, or hypertension (based on diagnosis indicators from claims) who receive olanzapine, the least appropriate antipsychotic when these conditions are present due to its metabolic effects.
Time frame: Up to 4 years
Antipsychotic doses as defined as excessive by CMS standards for nursing home residents with dementia
Time frame: Up to 2 years
Benzodiazepine use. Time frame differs because Medicare Part D did not pay for these drugs until 2013.
Time frame: Up to 4 years
Quetiapine or clozapine use only among antipsychotic users with Parkinson's disease or Lewy body dementia. These are the most appropriate antipsychotics in these conditions.
Time frame: Up to 4 years
Antipsychotic use in people with dementia. This is a subgroup analysis of the nursing home population.
Time frame: Up to 4 years
Proportion of antipsychotic users with evidence of a potentially appropriate indication, stratified by indication, as follows: verbal or physical aggression, delusions, hallucinations, delirium
Time frame: Up to 4 years
Antipsychotic use in those without a potentially appropriate indication, and proportion of those users with evidence of an inappropriate indication
Time frame: Up to 4 years
Antipsychotic use in those with a recent history of falls (fall indicator on any MDS assessment in the prior 6 months)
Time frame: Up to 4 years
Antipsychotic use in nursing home residents with an unsteady gait, as evaluated by MDS records
Time frame: Up to 4 years
Hypnotic use as measured by MDS indicator
Time frame: Up to 4 years
Changes in behavioral symptom frequency (each of verbal aggression, physical aggression, delirium, hallucinations, delusions)
Ryan M. Carnahan
Other
Extension Connection: Dissemination Effectiveness Evaluation
Acronym: ExConEval
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06347172
Alzheimer Disease, Brain Diseases
Boston, Massachusetts, United States
View Trial DetailsNCT07306065
Alzheimer Disease, Alzheimers Disease
Orlando, Florida, United States
View Trial DetailsNCT04992195
Alzheimer Disease, Arterial Thromboembolism
Hong Kong
View Trial DetailsNCT05529706
Alzheimer Disease, Brain Diseases
San Francisco, California, United States
View Trial Details